Tech1 outlet
Moderna's mRNA flu shot earns FDA approval after rollercoaster review
Moderna has received FDA approval for mFLUSIVA, its mRNA-based flu vaccine, marking a significant milestone for the company's expansion beyond COVID-19 vaccines. The vaccine is now authorized for use in all adults aged 50 and older, representing a new approach to flu prevention using messenger RNA technology.
Readers say
How does this story lean?
Outlet ratings above are Trace's curated source map. Vote here (same as on the home feed) — one vote per browser, changeable anytime. Rate individual outlets in the coverage list below.
How does this lean?
Comments
0No comments yet. Say what you noticed in the coverage.
Trending